This registry will make it possible to collect large-scale data on SAPL patients, particularly those treated with DOACs, in order to better assess the frequency of thrombotic and hemorrhagic events in this population of "non-high-risk" thrombotic SAPL patients treated with DOACs. The results will help refine treatment recommendations and could form the basis of future clinical trials.
In this study, there will be no modification of the usual care and no additional follow-up. Follow-up will be carried out during the patient's usual visits in the context of his or her pathology, the frequency of which will be left to the discretion of the usual physician. No additional consultations/hospitalizations/examinations will be carried out as part of the study. Data normally recorded in the medical record will be collected over a 5-year period, in line with standard patient follow-up.
Person having received complete information on the organization of the research and not having opposed the use of this data
Male or female aged 18 and over;
Carrier of a thrombotic APS according to the Sydney classification criteria, regardless of the length of time in the disease
Having received a direct oral anticoagulant (DOAC) treatment which is currently discontinued.
Incomplete Sydney classification criteria
Presence of a triple antiphospholipid positivity
History of arterial thrombosis
Pregnant, parturient or nursing mother
Population of "non-high-risk" thrombotic SAPL patients treated with DOACs. Given current recommendations, SAPL patients at "high risk" of thrombosis (triple positivity, history of arterial thrombosis) should not be treated with DOACs and will not be included. Recruitment will be carried out via the departments authorized to manage these patients, at the time of their consultation or hospitalization. Patients will be invited to participate in the study as part of their regular follow-up visit. Services: services authorized to care for these patients within the open international investigator hospitals
Cohort
Prospective
"non-high risk" thrombotic APS patients treated with DOAC
Other interventionThere is no specific intervention in this study. Routine care data will be collected from patients with a 'non-high-risk' APS profile who are currently being treated with DOACs or have been in the past.
Frequency of thrombotic complications
Occurrence of thrombotic recurrence within 5 years of inclusion confirmed by a reference examination : * PE: CT angiography, ventilation / perfusion scintigraphy * Stroke: MRI or brain scan * Venous or peripheral arterial thrombosis: Doppler ultrasound, CT angiography, MRI * MI or cardiac microcirculatory impairment: ECG and troponin, coronary angiography, TTE, MRI * Skin: skin biopsy * Adrenal or intra-alveolar hemorrhage: CT scan or MRI
Risk Factors of thrombotic recurrence
Occurrence of a venous, arterial or microcirculatory thrombotic recurrence confirmed by a baseline examination (detailed in the primary endpoint)
Frequency of manifestations associated with APS (non-criteria manifestations according to the Sydney classification criteria)
Occurrence of non-criteria manifestations according to the Sydney criteria: thrombocytopenia, hemolytic anemia, valve disease, livedo, nephropathy due to APS, superficial venous thrombosis, chorea
Frequency of hemorrhages and other adverse events
Occurrence of hemorrhagic accident according to the definition of the International Society on Thrombosis and Haemostasis
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
